Chris Boerner, Bristol Myers Squibb CEO (Tierney L. Cross/Bloomberg via Getty Images)
April 24, 2025 11:29 AM EDT
Deals
Pharma

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Max Gelman

Senior Editor

Is Bris­tol My­ers Squibb ready to take on big deal­mak­ing again?

When CEO Chris Boern­er took over in late 2023, Bris­tol My­ers was in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Ver­san­t's lat­est biotech fo­cus­es on in­flam­ma­to­ry dis­eases

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Roche takes steps to pro­tect it­self from tar­iffs, while Sanofi hangs back

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Sanofi's Al­tuvi­i­io clos­ing in on block­buster sta­tus, Dupix­ent sales surge

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times